Clinical trial · Interventional
PET-CT/MRI in the Radiotherapy for Prostate Cancer
Pilot Study of the Incorporation of PET-CT/MRI in the Radiotherapy for Prostate Cancer
NCT02816840CI-TRIAL-00022771unknownPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The trial is to explore new and effective techniques in the treatment of prostate cancer and evaluate the role of PET-CT / MRI played in radiotherapy. Intensity modulated radiation therapy(IMRT) is adopted with all patients and the efficacy assessment for the prostate cancer will be examined with PET / CT or CT in three months after radiotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PET-CT | Radiation | — | UNRESOLVED |
| PET-MRI | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- PET-CT
- description
- Patients in this arm take radiotherapy positioning with PET-CT.
- interventionNames
- Radiation: PET-CT
- type
- EXPERIMENTAL
- label
- PET-MRI
- description
- Patients in this arm take radiotherapy positioning with PET-MRI.
- interventionNames
- Radiation: PET-MRI
- type
- NO_INTERVENTION
- label
- Computed Tomography
- description
- Patients in this arm take radiotherapy positioning with CT.
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with pathologically confirmed prostate cancer * Staged with Ⅲ-Ⅳ prostate cancer * Aged from 18 to 65 years old * Quality of life score (Karnofsky performance score) \> 70 * No distant metastasis * No serious internal diseases may affect the treatment plan * No previous history of prostate radiation therapy * Patients must be able to understand and be willing to sign a written informed consent document. Exclusion Criteria: * Distant metastasis * Accompanied by other malignancies * Previous history of prostate radiation therapy * Pregnant or lactating women * History of allergic reaction to iodinated, non-iodinated, and/or gadolinium contrast agents * Liver and kidney dysfunction * Pacemaker or other metallic devices that would prevent MRI imaging from being performed * Patients quit during the treatment or violate of the study protocol caused by other factors * Any reason that, in the option of the investigator, contraindicates that the patient participates in the study
References
Publications (0)
Data not yet available
No reference posted for this study.